CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 250.05 AUD 0.63% Market Closed
Market Cap: 121.1B AUD

During the last 3 months CSL Ltd insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 10% over this period (open performance analysis).

The last transaction was made on Feb 21, 2024 by Ms Samantha (Sam) Louise Lewis (Non-executive Director) , who bought 32.2k AUD worth of CSL shares.

Last Transactions:
Ms Samantha (Sam) Louise Lewis
Non-executive Director
AU$+32.2k
Ms Alison Mary Watkins
Non-Executive Director
AU$+48k
Dr Robert Andrew Cuthbertson
Chief Operating Officer
AU$+41.2k
Dr Brian Anthony Mcnamee
Non-Executive Director
AU$+97.4k
Ms Carolyn Judith Hewson
Non-Executive Director
AU$+54.8k
Professor Duncan John Maskell
Non-Executive Director
AU$+96.3k
Ms Marie Elizabeth Mcdonald
General Counsel and Company Secretary
AU$+41.2k
Dr Megan Elizabeth Clark
Independent Non-Executive Director
AU$+41.2k
Megan Clark
Director
AU$+49.9k
Paul Mckenzie
Chief Executive Officer
AU$+10.5m
Robert Cuthbertson
Executive Vice President, Chief Information and Digital Officer
AU$+312.4k
Paul Mckenzie
Chief Executive Officer
AU$+839.6k
Paul Mckenzie
Chief Executive Officer
AU$+1.4m
Paul Mckenzie
Chief Executive Officer
AU$-365.6k
Robert Cuthbertson
Executive Vice President, Chief Information and Digital Officer
AU$-5.3m
Brian Mcnamee
Senior Adviser and former Chief Executive
AU$-5.6m
Megan Clark
Director
AU$+78k
Robert Cuthbertson
Executive Vice President, Chief Information and Digital Officer
AU$+78k
Brian Mcnamee
Senior Adviser and former Chief Executive
AU$+184.5k
Marie Mcdonald
Non-Executive Director
AU$+79k
Alison Watkins
Non-Executive Director
AU$+90.9k
Bruce Brook
Non-Executive Director
AU$+51.9k
Duncan Maskell
Chief Executive Officer
AU$+182.1k
Carolyn Hewson
Non-Executive Director
AU$+101.6k
Duncan Maskell
Chief Executive Officer
AU$+80.1k
Megan Clark
Director
AU$+22.7k
Marie Mcdonald
Non-Executive Director
AU$+34.2k
Bruce Brook
Non-Executive Director
AU$+68.6k
Carolyn Hewson
Non-Executive Director
AU$+57.1k
Alison Watkins
Non-Executive Director
AU$+40k
Brian Mcnamee
Senior Adviser and former Chief Executive
AU$+81.1k
Robert Cuthbertson
Executive Vice President, Chief Information and Digital Officer
AU$+34.2k
View All Transactions

During the last 3 months CSL Ltd insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 10% over this period (open performance analysis).

The last transaction was made on Feb 21, 2024 by Ms Samantha (Sam) Louise Lewis (Non-executive Director) , who bought 32.2k AUD worth of CSL shares.

Sold
0-3
months
0 AUD
0
3-6
months
0 AUD
0
6-9
months
0 AUD
0
9-12
months
0 AUD
0
Bought
0-3
months
No Insider Transactions
0
0 AUD
3-6
months
No Insider Transactions
0
0 AUD
6-9
months
No Insider Transactions
0
0 AUD
9-12
months
No Insider Transactions
0
0 AUD

CSL Ltd
Insider Trading Chart

CSL Ltd
Last Insider Transactions

Global
Insiders Monitor

CSL Ltd
Glance View

Economic Moat
None
Market Cap
121.1B AUD
Industry
Biotechnology

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
222.99 AUD
Overvaluation 11%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top